ICON experts frequently author or contribute to industry trade press. The following are some recent articles.
DMCs: Maintaining data integrity in COVID-19 climate
A thought leadership article by ICON's Craig McLendon which considers the use of data monitoring committees to support clinical trial management and decision-making during the COVID-19 pandemic.
Thwarting Cyber attacks: Steps to implement security into mHealth development
A thought leadership piece authored by David Novotny, Marie McCarthy and Tony Clarke which considers the potential risks of cyber threats in mHealth.
Coronavirus vaccine: how pharma is picking up the pace
A PharmaPhorum article featuring commentary from ICON's Dr. Nuala Murphy and Dr. James Cummings.
COVID-19 will spur decentralised and hybrid trials – Novartis hails digital investment
An article featuring commentary from Dr. Nuala Murphy regarding the use of decentralised and hybrid trials during the COVID-19 crisis.
Transforming cell and gene therapy trial design and execution
With over 400 dedicated Cell and Gene Therapy professionals globally, ICON has developed tools and best practices to transform CGT trial design and execution.
COVID-19 vaccine response
James Cummings and Beth Tulip discuss developments in vaccine research efforts and key challenges of delivering a coronavirus vaccine.
Five common literature reviews for RWE generation
A discussion of five popular types of RWE literature reviews, including timing, strengths, limitations and applications.
Translation services and the race for a coronavirus vaccine
An article featuring commentary from Adelina Lear regarding the role of language services in the drug development lifecycle.
ICON launches Coronavirus Observatory
This article discusses ICON’s Coronavirus Observatory, a tool providing real-time updates on COVID-19 vaccine trials, and insights into key issues.
The Home Depot, the TJX Companies and ICON PLC: Three safe stocks in a stormy market
An article highlighting three safe stocks to buy that have been largely unaffected by market turmoil due to COVID-19.